Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 84 Publications

Nature, 2018, 560(7718):372-376

PubMed: 30046109

Nature, 2017, 543(7647):728-732

PubMed: 28321130

Nature, 2017, 728-732

PubMed: 28321130

Nature, 2012, 487(7408):505-9

PubMed: 22763448

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590

Blood, 2011, 118(14):3911-21

PubMed: 21821710

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691
Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831
Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062

Oncogene, 2012, 33(2):236-45

PubMed: 23246970

Cancer Lett, 2015, 359(1):47-56

PubMed:

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424
Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957

FASEB J, 2014, fj.13-247924

PubMed: 24903273

Exp Mol Med, 2013, 45:e64

PubMed: 24263233

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272
J Mater Chem B, 2013, 5602-5610

PubMed:

J Virol, 2014, 88(9):5152-64

PubMed: 24574393

J Virol, 2012, 86(8):4578-85

PubMed: 22345463

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602
Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345

Open Biol, 2015, 5(3)

PubMed: 25761368

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720

PLoS One, 2014, 9(2):e88587

PubMed: 24523919

PLoS One, 2014, 9(9):e105919

PubMed: 25221930
PLoS One, 2014, 9(8):e105280

PubMed: 25144531

PLoS One, 2014, 9(9):e108193

PubMed: 25247710

PLoS One, 2013, 8(3):e59879

PubMed: 23533654

PLoS One, 2012, 7(9):e46518

PubMed: 23029544

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed:

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318

Animal, 2016, 10(8):1319-27

PubMed: 26956906

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388

11 Customer Reviews

Level of phospho-proteins in RTK and PI3K–Akt–mTOR pathways in treated tumours, detected with western blot.

Nature, 2017, 728-732. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

A, ANOVA of IC50 values of the dual PI3K/mTOR inhibitor NVP-BEZ235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and Braf wild-type cells. B, decreases in pAkt and pP70S6K in a dose and time-dependent fashion in 2 melanoma cell lines treated with NVP-BEZ235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependent fashion. C, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ235 at different concentrations. NVPBEZ235 was effective in inhibiting colony formation at low nanomolar concentrations.

Clin Cancer Res 2010 16, 6029-6039. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Relative kinase activities of p110α mutants and the inhibitory effect of PI3K inhibitors against hotspot mutants of p110α. A, recombinant FLAG-tagged PI3K p110α/p85α protein complex produced in 293T cells was immunoprecipitated , and the immunoprecipitates were used for the quantitative PI3K-HTRF assay (32).

B, effect of three PI3K inhibitors (ZSTK474, LY294002, and NVP-BEZ235) on the enzymatic activity of two hotspot mutants (E545K and H1047R) p110α compared with the wild-type. No striking difference was observed in the IC50 concentrations of these inhibitors between wild-type and mutant p110α.

Cancer Res 2010 70, 4982-4994. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

ZSTK474 and GDC-0941 selectively inhibit class I PI3K over mTOR. (A) Inhibition profiles of the selected five PI3K inhibitors for mTOR. Data shown are mean±SD (n = 3), representative of 2 or 3 independent experiments. (B) IC50 values of the PI3K inhibitors for mTOR. (C) Selectivity of each PI3K inhibitor for PI3Ka over mTOR. The selectivity index is expressed as the ratio of the IC50 value for mTOR over that for PI3Ka. The IC50 values of ZSTK474, NVP-BEZ235 and LY294002 for PI3Ka are 0.016, 0.007 and 0.6 μM, respectively, as reported previously by us.

Eur J Cancer 2010 46, 1111-1121. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Three-dimensional responses of MCF7/IGF-1R cells to TAM (1 μM), E2 and IGF-1. Compared to parental MCF7 cells (a), MCF7/IGF-1R cells (b) in three-dimensional (3D) culture formed bigger acini in response to IGF-1 stimulation and displayed significant TAM resistance when treated with TAM (1 μM) + E2 + IGF-1, which was removable by kinase inhibitors BMS-536924, U0126 and BEZ235 (c). Cells (10,000/well) were seeded in 96-well plates. Acini were formed on 100% Matrigel and cultured for 14 days in starving medium containing 2% Matrigel and 5% charcoal/dextran-stripped fetal bovine serum with the treatments as indicated. Concentrations used: TAM (1 μM), E2 (1 nM) and IGF-1 (100 ng/mL). Confocal image original magnification, × 20. Red, rhodamine phalloidin (actin). Blue, Hoechst blue stain. Results are representative of two individual experiments.

Breast Cancer Res 2011 13, R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

TAM (10 nM) agonistic behavior in MCF7/IGF-1R cells is not inhibited by phosphatidylinositol 3-kinase/Akt inhibitor BEZ235. (a) Inhibitory effects of kinase inhibitors BMS-536924, U0126 and BEZ235 on agonistic effect of TAM (10 nM) in the presence of IGF-1 (100 ng/mL). **P < 0.01. (b) Inhibitory effects of phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor BEZ235 at various dose ranges on IGF-1R signaling. (c) Agonistic behavior of TAM (10 nM) in response to BEZ235 kinase inhibitor. (-), no BEZ235. Results are representative of three independent experiments. Data are expressed as means ± SD.

Breast Cancer Res 2011 13:R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
(B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

Transl Oncol, 2016, 9(3):197-202. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

The effects of LY294002, rapamycin and NVP-BEZ235 on activation of PI3K-Akt-mTOR pathway in hepatocytes. (a) The mRNA expression (PI3K, Akt, mTOR, raptor) by Real-Time PCR, (b) protein expression (PI3K, Akt, mTOR, S6K) by ELISA kits; (c) protein expression of S6K and P-S6K by western blotting. The different letters indicated significant differences (P <0.05). LY = LY294002; rapa = rapamycin; NVP = NVP-BEZ235.

Animal, 2016, 10(8):1319-27. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
FIG. 4. Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts. The bar graph shows the quantification of the immunoblots (mean±SD). PLA2G4A, Ethanolamine kinase 1 and 2 (ETNK1/2), Choline kinase alpha/beta (ChoKA/B), and β-actin protein expression were examined by immunoblotting of tissue samples after MRS experiments [control group (n= 5) and BEZ235-treated group (n=7)]. This demonstrated a higher expression of PLA2G4A protein ( P=0.005), but no changes in ETNK1 and ChoKA/B in samples from basal-like xenografts treated with BEZ235.

Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	M4PvO2FvfGmvaXPyc4Jq[WxiQYPzZZk>		NWrVclJrOThiaB?=	MV7EUXNQ	NFLQRlVCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JJdqfGhiRVO1NEBw\iByLkCwNlUh\|ryP	M3H3TlI1QDB3OUS2
MCF7	M2HN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTaPVRVOC5yMT2xNFAh\|ryP	M3vSVFQ5KGh?	MmfFSG1UVw>?	Mn;lTWM2OD1yLkezJO69VQ>?	NIj6bI0zOzh5MUmwOC=>
HCT116	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHtSlQxNjBzLUGwNEDPxE1?	M3rCbVQ5KGh?	NHXHdXlFVVOR	Mn\HTWM2OD1zLkG2JO69VQ>?	NIPuXYIzOzh5MUmwOC=>
U87MG	M4jOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVywMlAyNTFyMDFOwG0>	MXu0PEBp	NH:zO4pFVVOR	NE\0elVKSzVyPUGuN\|Ih\|ryP	Mn75NlM5PzF7MES=
HBC4	NGfHboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPXV5cxNjBzLUGwNEDPxE1?	NETp[no1QCCq		NF3FVVBNd2diR1m1NF0uQC54MTDN	M4C2[lIzOzN4MkS2
BSY1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjxPJoxOC5yMT2xNFAh\|ryP	MWi0PEBp		MmnEUI9oKEeLNUC9MVgvPDhiTR?=	NX;pO3p4OjJ\|M{[yOFY>
HBC5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTmNE4xOS1zMECg{txO	NVPxWVNoPDhiaB?=		MUjMc4chT0l3ME2tO{45PyCP	M3PC[lIzOzN4MkS2
MCF7	M3W3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDtboVZOC5yMT2xNFAh\|ryP	MYC0PEBp		NYHYU4h6VG:pIFfJOVA:NThwMU[gUS=>	Ml\WNlI{OzZ{NE[=
MDA-MB-231	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXWwMlAyNTFyMDFOwG0>	M1zHOFQ5KGh?		MW\Mc4chT0l3ME2tPE4xQSCP	Ml7kNlI{OzZ{NE[=
U251	NIHEV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH4NE4xOS1zMECg{txO	NX3NXYtvPDhiaB?=		NXrWfIU{VG:pIFfJOVA:NTdwNk[gUS=>	M2LSe\|IzOzN4MkS2
SF268	M4jL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PObFAvODFvMUCwJO69VQ>?	NWD5PYJjPDhiaB?=		MYnMc4chT0l3ME2tO{46OiCP	MnfvNlI{OzZ{NE[=
SF295	M2PweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrS[Y1COC5yMT2xNFAh\|ryP	NFvmUZA1QCCq		NFPocWpNd2diR1m1NF0uQC5\|MTDN	NV\WelBNOjJ\|M{[yOFY>
SF539	NIiyVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrVVYtmOC5yMT2xNFAh\|ryP	Mo\4OFghcA>?		MVzMc4chT0l3ME2tPE42QSCP	MUCyNlM{PjJ2Nh?=
SNB75	NYPhd2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUniT\|h5OC5yMT2xNFAh\|ryP	NIrI[Xo1QCCq		MYjMc4chT0l3ME2tPE42QCCP	MWKyNlM{PjJ2Nh?=
SNB78	NVjlfI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHnNWE3OC5yMT2xNFAh\|ryP	MnXNOFghcA>?		MkHCUI9oKEeLNUC9MVgvPjViTR?=	NX;3U\|cxOjJ\|M{[yOFY>
HCC2998	M1GwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T0ZVAvODFvMUCwJO69VQ>?	MlnLOFghcA>?		MYjMc4chT0l3ME2tPE4xPSCP	NILwdWkzOjN\|NkK0Oi=>
KM12	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSwMlAyNTFyMDFOwG0>	MUS0PEBp		MlrEUI9oKEeLNUC9MVcvPTRiTR?=	NULkVFBJOjJ\|M{[yOFY>
HT-29	NIizUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXuxU4tIOC5yMT2xNFAh\|ryP	M1fUVlQ5KGh?		NH7zOVBNd2diR1m1NF0uPy55NTDN	NEjGOpczOjN\|NkK0Oi=>
HCT15	NVnUbXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorZNE4xOS1zMECg{txO	NFrPO5M1QCCq		MWTMc4chT0l3ME2tPE4xOyCP	NVLZTlJUOjJ\|M{[yOFY>
HCT116	M17tVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDvNE4xOS1zMECg{txO	NW\Dc\|FWPDhiaB?=		MVPMc4chT0l3ME2tO{43OSCP	NYT4UWxbOjJ\|M{[yOFY>
NCI-H23	NH7FPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnPUVgxNjBzLUGwNEDPxE1?	NWjaXo1NPDhiaB?=		MXrMc4chT0l3ME2tO{43PCCP	NWewWXFmOjJ\|M{[yOFY>
NCI-H226	NGXiW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fw[FAvODFvMUCwJO69VQ>?	NXjXe2ttPDhiaB?=		NGfZS41Nd2diR1m1NF0uQC52NDDN	NGf4R5QzOjN\|NkK0Oi=>
NCI-H522	M3nhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1n4OlAvODFvMUCwJO69VQ>?	NEjpcnk1QCCq		NGTYZohNd2diR1m1NF0uQC52NTDN	NIfWWmkzOjN\|NkK0Oi=>
NCI-H438	NX3OdHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmX3NE4xOS1zMECg{txO	M1TyTFQ5KGh?		Ml7yUI9oKEeLNUC9MVgvOTFiTR?=	NYTqfo5pOjJ\|M{[yOFY>
A549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXiwMlAyNTFyMDFOwG0>	NFHxUIg1QCCq		M3X0S2xw\yCJSUWwQU05NjB5IF2=	NXSwdVl5OjJ\|M{[yOFY>
DMS273	NETBdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKz[pdMOC5yMT2xNFAh\|ryP	NETET5E1QCCq		MnezUI9oKEeLNUC9MVcvQDBiTR?=	NIHINmkzOjN\|NkK0Oi=>
DMS114	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG1ZWtmOC5yMT2xNFAh\|ryP	M3j2b\|Q5KGh?		MX3Mc4chT0l3ME2tPE4{QSCP	NIm3PXgzOjN\|NkK0Oi=>
LOXIMVI	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:4XlAvODFvMUCwJO69VQ>?	NGjvb2Y1QCCq		NETMSFRNd2diR1m1NF0uQC54NjDN	M{\lOVIzOzN4MkS2
OVCAR3	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D2eFAvODFvMUCwJO69VQ>?	M3TVfFQ5KGh?		M{HMVWxw\yCJSUWwQU05NjF5IF2=	M3Gz[\|IzOzN4MkS2
OVCAR4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmwMlAyNTFyMDFOwG0>	MUO0PEBp		M1\kWWxw\yCJSUWwQU05NjV6IF2=	NF\ONnAzOjN\|NkK0Oi=>
OVCAR5	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7H[Iw4OC5yMT2xNFAh\|ryP	M{ntblQ5KGh?		MoTZUI9oKEeLNUC9MVcvPTdiTR?=	MkX5NlI{OzZ{NE[=
OVCAR8	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i0e\|AvODFvMUCwJO69VQ>?	M4K3UVQ5KGh?		NGXQXoZNd2diR1m1NF0uPy56NDDN	NV\ZbHBNOjJ\|M{[yOFY>
SKOV3	NHPQVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPRNE4xOS1zMECg{txO	MljrOFghcA>?		MnLlUI9oKEeLNUC9MVgvPDFiTR?=	NWjYWGd2OjJ\|M{[yOFY>
RXF631L	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2m2SFAvODFvMUCwJO69VQ>?	MWW0PEBp		MXXMc4chT0l3ME2tPE4zOSCP	NWfOO242OjJ\|M{[yOFY>
ACHN	NUHCR\|dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnWfWFLOC5yMT2xNFAh\|ryP	NWXIWpVMPDhiaB?=		Mkn2UI9oKEeLNUC9MVcvQTViTR?=	NGPBT2QzOjN\|NkK0Oi=>
St-4	Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTEfFM{OC5yMT2xNFAh\|ryP	NUDCTZVKPDhiaB?=		NG\Ge4pNd2diR1m1NF0uPy52NzDN	Mo[4NlI{OzZ{NE[=
MKN1	NXTuZlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\MNE4xOS1zMECg{txO	NGjGVIM1QCCq		NF3odVFNd2diR1m1NF0uQC52MTDN	MoLINlI{OzZ{NE[=
MKN7	NWHXT\|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEGwS3MxNjBzLUGwNEDPxE1?	NHe2T\|U1QCCq		MVHMc4chT0l3ME2tO{43QCCP	NFf3dHUzOjN\|NkK0Oi=>
MKN28	M4LzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPwcnM{OC5yMT2xNFAh\|ryP	Ml\SOFghcA>?		M{XzXWxw\yCJSUWwQU04NjB5IF2=	NVLQ[mpnOjJ\|M{[yOFY>
MKN45	NYPkWlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D5bFAvODFvMUCwJO69VQ>?	NWr5TpRqPDhiaB?=		MXnMc4chT0l3ME2tPE4{PCCP	NUfYSZhuOjJ\|M{[yOFY>
MKN74	M3f5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnBWpcxNjBzLUGwNEDPxE1?	M3vzWFQ5KGh?		NInGdJhNd2diR1m1NF0uPy52MjDN	NXLLdHM5OjJ\|M{[yOFY>
DU145	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDWT2ExNjBzLUGwNEDPxE1?	NXLHToZrPDhiaB?=		MWPMc4chT0l3ME2tPE4yPiCP	NF3oWXUzOjN\|NkK0Oi=>
PC3	M{DjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP0OJIxNjBzLUGwNEDPxE1?	MlTIOFghcA>?		MluxUI9oKEeLNUC9MVgvPjZiTR?=	NHT0RYUzOjN\|NkK0Oi=>
Trypanosoma brucei brucei	MmrGSpVv[3Srb36gRZN{[Xl?	MVyyNFAhdk1?	NVPidppJOTJiaB?=	MnPrSG1UVw>?	NXS5b4xMTGWlcnXhd4UhcW5icHjvd5Bpd3SrZInsJIlvd3OrdH;sJJBpd3OyaHH0[UBt\X[nbB?=	NUXRPFJsOjR6MEW5OFY>
Trypanosoma brucei brucei	M1znUmZ2dmO2aX;uJGF{e2G7		MmDKNVghcA>?	MX3EUXNQ	Mn7aTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	M4X4OlI1QDB3OUS2
Trypanosoma brucei brucei	M3jhNGZ2dmO2aX;uJGF{e2G7	M3;1N\|IxOCCwTR?=	MlLSNVIhcA>?	MmjQSG1UVw>?	MlfGSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	Ml7wNlQ5ODV7NE[=
Trypanosoma brucei brucei	M{TON2Z2dmO2aX;uJGF{e2G7	NFzF[GYzODBibl2=	M1zlTlEzKGh?	MkS4SG1UVw>?	NF21NodG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	NG\CWZYzPDhyNUm0Oi=>
UM-UC-3	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDVR45iUUN3ME2zNVUheE1?	NVXjVmZsW0GQR1XS
SBC-1	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTd2MjDwUS=>	M3q5WHNCVkeHUh?=
MKN1	NGTUPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf1Z21KSzVyPUKuPEBvVQ>?	NF2yeWRUSU6JRWK=
NCI-H720	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PBNmlEPTB;Mz61O{BvVQ>?	MUTTRW5ITVJ?
BFTC-909	NEHIbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjqVlZpUUN3ME2zMlcyKG6P	M2jYWnNCVkeHUh?=
BPH-1	NX\rb2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfxTWM2OD12Lke2JI5O	MYPTRW5ITVJ?
PC-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fteGlEPTB;NT6wPUBvVQ>?	MYTTRW5ITVJ?
AN3-CA	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTVwNU[gcm0>	NH:3[2dUSU6JRWK=
HN	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nGWGlEPTB;NT65OkBvVQ>?	M171UHNCVkeHUh?=
HCC2218	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmriTWM2OD14Lk[xJI5O	MVnTRW5ITVJ?
KP-4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnle45MUUN3ME23JI5O	MnXmV2FPT0WU
LU-139	M4nCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLQTWM2OD15Lke3JI5O	NWnR[IZvW0GQR1XS
ETK-1	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjIZXNKSzVyPUeuPFghdk1?	MoTIV2FPT0WU
Ramos-2G6-4C10	M3\iS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfINVhJUUN3ME24MlQ6KG6P	MlzaV2FPT0WU
MHH-PREB-1	NF3JSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHJ[o1KSzVyPUmuNVIhdk1?	NETaXohUSU6JRWK=
DU-4475	NWnuTVluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDRcZZ6UUN3ME25MlQ1KG6P	M{XsSnNCVkeHUh?=
NCI-H1666	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLZRmc2UUN3ME25MlcyKG6P	MlzIV2FPT0WU
CAMA-1	NUTIU2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n2XGlEPTB;OT64JI5O	MWXTRW5ITVJ?
TYK-nu	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjnVlg1UUN3ME25Mlk1KG6P	NIrWdIlUSU6JRWK=
MFE-280	NXnDellPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjtTWM2OD17Lkm5JI5O	MlHhV2FPT0WU
A549	NFPFWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjJTWM2OD1zMD6xOEBvVQ>?	M331W3NCVkeHUh?=
769-P	NUHqdHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHiTWM2OD1zMD60OEBvVQ>?	MV\TRW5ITVJ?
L-363	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml72TWM2OD1zMD62PUBvVQ>?	NIq0W\|dUSU6JRWK=
ES8	NILYXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrmTWM2OD1zMD65JI5O	MXfTRW5ITVJ?
PA-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTFzLkiyJI5O	MWHTRW5ITVJ?
Mewo	NUXBOoRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLNRlMyUUN3ME2xNU46QSCwTR?=	MkO4V2FPT0WU
HSC-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT0TWM2OD1zMj6yNUBvVQ>?	NFnDSIFUSU6JRWK=
H4	NFztTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFf2Vo9KSzVyPUGyMlY4KG6P	MYHTRW5ITVJ?
BB65-RCC	M1PpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVGxe2tRUUN3ME2xNk44OiCwTR?=	MXjTRW5ITVJ?
NCI-H1793	NW[5b2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjHTWM2OD1zMj64NkBvVQ>?	M4XTOXNCVkeHUh?=
KARPAS-45	NYDJOo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j0TmlEPTB;MUOuOVEhdk1?	Ml[0V2FPT0WU
GCT	NEjNfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\uTWM2OD1zMz62PEBvVQ>?	NYHjV5JtW0GQR1XS
EoL-1	NEXIOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXeyWVJ6UUN3ME2xN{46OyCwTR?=	NHX2PHNUSU6JRWK=
LB2241-RCC	M13IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X2bmlEPTB;MUSuNFEhdk1?	MUXTRW5ITVJ?
ES5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7MVWVKSzVyPUG0Mlc1KG6P	M2TF[nNCVkeHUh?=
LOXIMVI	M1\idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrrSopKSzVyPUG0Mlk6KG6P	MlWyV2FPT0WU
COR-L105	M3frXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XxcGlEPTB;MUWuNFQhdk1?	NXTNflRFW0GQR1XS
P12-ICHIKAWA	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF3LkGgcm0>	MW\TRW5ITVJ?
CHL-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PTSWlEPTB;MUWuOFUhdk1?	MWTTRW5ITVJ?
VMRC-RCZ	NWS1Tml3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTF3Lk[zJI5O	Ml7DV2FPT0WU
HH	M3zxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfUZW5jUUN3ME2xOU44KG6P	NWHCSmNqW0GQR1XS
NUGC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXtTWM2OD1zNj6zOEBvVQ>?	MVLTRW5ITVJ?
EGI-1	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF4LkSzJI5O	NXj2eVRuW0GQR1XS
OS-RC-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvBTWM2OD1zNj60O{BvVQ>?	M3zsWHNCVkeHUh?=
MOLT-16	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF5LkG1JI5O	MljKV2FPT0WU
NCI-H209	NUHEd3BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHRXVhKSzVyPUG3MlI6KG6P	M2HlRnNCVkeHUh?=
697	NH[1eo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XOWmlEPTB;MUeuOFMhdk1?	Ml71V2FPT0WU
D-56MG	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF5Lk[5JI5O	NVHCVWlZW0GQR1XS
VA-ES-BJ	M{PWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF5LkizJI5O	NXL3R49pW0GQR1XS
EW-16	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrXSnFPUUN3ME2xPE4xPCCwTR?=	NXHxUGxJW0GQR1XS
HGC-27	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TkVGlEPTB;MUiuNFYhdk1?	MX3TRW5ITVJ?
ES7	NGHPenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\BZoF{UUN3ME2xPE4xQSCwTR?=	M2nib3NCVkeHUh?=
HuH-7	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF6LkSgcm0>	M4X5OXNCVkeHUh?=
BCPAP	M3nhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi0XoJKSzVyPUG4MlY2KG6P	MXLTRW5ITVJ?
SW1710	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES3cIxKSzVyPUG4MlczKG6P	MkLOV2FPT0WU
IST-MEL1	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\UR2lEPTB;MUiuO\|chdk1?	NX\ENVJEW0GQR1XS
SF295	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofkTWM2OD1zOD65N{BvVQ>?	NXO1UIpRW0GQR1XS
RPMI-7951	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7xN3NyUUN3ME2xPU4zQCCwTR?=	M4HqbHNCVkeHUh?=
SF126	M4r4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fv[2lEPTB;MUmuOFEhdk1?	NVHDeFI2W0GQR1XS
GAMG	NI\FS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjYWXI2UUN3ME2xPU41QCCwTR?=	NFrzZ2FUSU6JRWK=
KNS-81-FD	M3HFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTF7LkW0JI5O	MkL3V2FPT0WU
RT-112	NEjZfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLRTWM2OD1zOT62OkBvVQ>?	NELFRnNUSU6JRWK=
DEL	Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjOS5lKSzVyPUKwMlQ6KG6P	MXjTRW5ITVJ?
CGTH-W-1	M1qwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJyLk[zJI5O	NFm5ZoNUSU6JRWK=
HOS	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJzLkC2JI5O	NUTCc\|c2W0GQR1XS
ES4	M13nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLaToZ1UUN3ME2yNU4xQCCwTR?=	M3zsPHNCVkeHUh?=
RXF393	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLPTWM2OD1{MT60OUBvVQ>?	MWXTRW5ITVJ?
NCI-H2030	NXOyfoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWH4TYR{UUN3ME2yNU42OiCwTR?=	MnLiV2FPT0WU
YH-13	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\YNmRuUUN3ME2yNU45QCCwTR?=	NULLU2N4W0GQR1XS
HT-1080	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3oZZVKSzVyPUKxMlk{KG6P	NUDhZXV3W0GQR1XS
NCI-SNU-1	M2nFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJzLkm1JI5O	NIO5XXRUSU6JRWK=
G-402	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjxTWM2OD1{Mj6xOkBvVQ>?	NInSfmdUSU6JRWK=
786-0	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7HV2ZKSzVyPUKyMlI6KG6P	NFTWcJVUSU6JRWK=
ME-180	NWPQRZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nmbGlEPTB;MkKuOFMhdk1?	MWfTRW5ITVJ?
NB69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPkS2FKSzVyPUKyMlU{KG6P	NUHET29WW0GQR1XS
J-RT3-T3-5	NFXGUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2exdGlEPTB;MkKuPVYhdk1?	MXLTRW5ITVJ?
TGBC1TKB	NWL1[VVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInrT\|FKSzVyPUKzMlA2KG6P	MW\TRW5ITVJ?
SW780	NX7YbW9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ\|LkGzJI5O	NYrtdlJHW0GQR1XS
MG-63	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnpWJNKSzVyPUKzMlQ2KG6P	M1j2[nNCVkeHUh?=
BV-173	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;6THJpUUN3ME2yN{45PyCwTR?=	M1vpeHNCVkeHUh?=
CAL-51	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jkdmlEPTB;MkOuPFkhdk1?	NGPVW3NUSU6JRWK=
A375	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3BTWM2OD1{Mz65N{BvVQ>?	NXzpOHVyW0GQR1XS
MEL-HO	M{nwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjod3NKSzVyPUK0MlA1KG6P	NXvCS2pMW0GQR1XS
EFO-27	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3LTWM2OD1{ND6zN{BvVQ>?	NYrrSFk1W0GQR1XS
Hs-578-T	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ2LkW4JI5O	NHfhXphUSU6JRWK=
NBsusSR	NIrPV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJ2Lk[gcm0>	MYrTRW5ITVJ?
CTB-1	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXIZ5dDUUN3ME2yOE43PyCwTR?=	NUmxXYNSW0GQR1XS
FTC-133	M1L4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfWfnZKSzVyPUK1MlEhdk1?	NULkdJNDW0GQR1XS
MOLT-4	M2f2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVu4[FBlUUN3ME2yOU4yOiCwTR?=	M{DOcHNCVkeHUh?=
HO-1-N-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJ3LkG1JI5O	MmrjV2FPT0WU
ES3	NX3LOWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXlTWM2OD1{NT6yNkBvVQ>?	M{XMV3NCVkeHUh?=
TI-73	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPQ[3pOUUN3ME2yOU4zQCCwTR?=	M1SydXNCVkeHUh?=
MPP-89	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH2d2tKSzVyPUK1MlMzKG6P	NXroRVZxW0GQR1XS
KYSE-150	NFHEeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTUO\|VKSzVyPUK1Mlg6KG6P	NHTFN3NUSU6JRWK=
LXF-289	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzuTWM2OD1{Nj6wOEBvVQ>?	NIThVJpUSU6JRWK=
SK-LU-1	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJ4LkG3JI5O	M4P3[XNCVkeHUh?=
HOP-92	NH3Fbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJ4LkS4JI5O	MoTHV2FPT0WU
HuO9	M1SzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJ4Lke2JI5O	MnX4V2FPT0WU
SW962	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkGzTWM2OD1{Nj63OkBvVQ>?	NEXHepFUSU6JRWK=
RS4-11	M1fXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjoR49KSzVyPUK2MlkyKG6P	Ml\ZV2FPT0WU
NCI-H292	M2Ljbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TDc2lEPTB;Mkegcm0>	NU\3eJFCW0GQR1XS
DB	NU\WXJBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJ5LkO2JI5O	MYTTRW5ITVJ?
SW1088	NVLmeZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJ6LkK5JI5O	NF\rcmpUSU6JRWK=
A204	NEPYe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzWU4lqUUN3ME2yPE41PyCwTR?=	MYjTRW5ITVJ?
A3-KAW	M3\JZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXu[lZ{UUN3ME2yPE43PCCwTR?=	NY\qW5RNW0GQR1XS
MV-4-11	NUjmc5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJ6Lkegcm0>	MVnTRW5ITVJ?
ES1	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2qxU2lEPTB;MkiuPFQhdk1?	NVTjdYt1W0GQR1XS
ONS-76	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPXTWM2OD1{OT6wOUBvVQ>?	M2DM[nNCVkeHUh?=
D-263MG	NF3DfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rh[2lEPTB;MkmuN\|Uhdk1?	NXLXNZRPW0GQR1XS
U-2-OS	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXtbm1KSzVyPUK5MlUhdk1?	M1;3fXNCVkeHUh?=
T98G	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\PdWFZUUN3ME2yPU45QCCwTR?=	MYPTRW5ITVJ?
GI-ME-N	NIXsW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvD[ZB6UUN3ME2yPU46OSCwTR?=	NGnIN\|VUSU6JRWK=
BHT-101	MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PXOGlEPTB;M{CuNFUhdk1?	NXfkRWRpW0GQR1XS
NOS-1	NG\WOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLsNW5HUUN3ME2zNE4yOiCwTR?=	MlOwV2FPT0WU
AsPC-1	MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\Pb5dKSzVyPUOwMlIhdk1?	M4DUWHNCVkeHUh?=
QIMR-WIL	NFL4XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvhU4RTUUN3ME2zNE43KG6P	NX7vNnR4W0GQR1XS
JVM-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP3SJVKSzVyPUOwMlg{KG6P	NFfGPZFUSU6JRWK=
KU-19-19	NVjtW\|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rlcGlEPTB;M{GuNVMhdk1?	MnzWV2FPT0WU
OVCAR-8	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTNzLkK2JI5O	NHLyfIxUSU6JRWK=
BEN	NWTkZlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT3dJhKSzVyPUOxMlY{KG6P	MV\TRW5ITVJ?
BE-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW2TWM2OD1\|MT64NkBvVQ>?	NFnpcHNUSU6JRWK=
EW-18	M{XPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3Pd4ZQUUN3ME2zNU45PiCwTR?=	MYjTRW5ITVJ?
ECC10	M3P0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGxRmtpUUN3ME2zNU46PSCwTR?=	M4LSTHNCVkeHUh?=
CTV-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTN{LkiyJI5O	MmjWV2FPT0WU
COLO-800	NGrNPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTN{LkmyJI5O	NXrjd4VuW0GQR1XS
A2058	M{\xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTwT2JYUUN3ME2zN{4zPSCwTR?=	M13F[3NCVkeHUh?=
VM-CUB-1	NF21TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTN\|LkSzJI5O	NY[5fldkW0GQR1XS
Ca9-22	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[5[GtKSzVyPUOzMlU2KG6P	NXSyNFh1W0GQR1XS
COLO-684	NU\TR4k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXVTWM2OD1\|Mz61PEBvVQ>?	NVfnOHh6W0GQR1XS
RPMI-8226	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTN\|LkiyJI5O	MULTRW5ITVJ?
SK-NEP-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTN2LkG1JI5O	MoH4V2FPT0WU
Becker	M{fvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfsTWM2OD1\|ND6yNUBvVQ>?	NUnhfZllW0GQR1XS
NCI-H28	NWr1N\|RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nYRWlEPTB;M{SuOFQhdk1?	M{TjPHNCVkeHUh?=
CAL-120	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3X3[GlEPTB;M{SuO\|Ihdk1?	NXLZfoRrW0GQR1XS
MDA-MB-157	NXTjXGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPZTWM2OD1\|NT60NUBvVQ>?	NXfYe5BsW0GQR1XS
OVCAR-5	NGHwNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\tU2lEPTB;M{WuOFchdk1?	NFrtcoRUSU6JRWK=
LAMA-84	NGrE[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojzTWM2OD1\|NT64O{BvVQ>?	MX;TRW5ITVJ?
CAKI-1	NWrpdXBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofQTWM2OD1\|Nj60N{BvVQ>?	M1[ycHNCVkeHUh?=
Daoy	M4r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTkXVFKSzVyPUO2Mlchdk1?	NUS3bWFpW0GQR1XS
CAL-62	M1PqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\SNFRvUUN3ME2zOk45PiCwTR?=	MoS5V2FPT0WU
8-MG-BA	NWq0cohjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN5LkK1JI5O	NWn3T5prW0GQR1XS
8505C	NYTiUY41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PFZmlEPTB;M{euOVEhdk1?	Mln0V2FPT0WU
LNCaP-Clone-FGC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmn2TWM2OD1\|Nz61PUBvVQ>?	MojxV2FPT0WU
CAL-39	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN5Lkmgcm0>	MmrRV2FPT0WU
MN-60	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTN5Lkm2JI5O	NYXzTJJiW0GQR1XS
RKO	NUG5cFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHO1fnhKSzVyPUO4MlM{KG6P	NUG4b3RmW0GQR1XS
U251	M1fnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoW3TWM2OD1\|OD60N{BvVQ>?	MU\TRW5ITVJ?
SJSA-1	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTN6LkW0JI5O	MkPyV2FPT0WU
CAL-12T	NIX0SolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7XV\|lYUUN3ME2zPE43KG6P	NYXB[nc3W0GQR1XS
HCC1419	NWPiN\|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf1S3pxUUN3ME2zPE44OSCwTR?=	MlvsV2FPT0WU
CO-314	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH2TWM2OD1\|OD63OEBvVQ>?	MXrTRW5ITVJ?
LB1047-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nU[GlEPTB;M{iuPFEhdk1?	NVXLcmViW0GQR1XS
A101D	NVHzSZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4L3TGlEPTB;M{iuPVchdk1?	MULTRW5ITVJ?
MDA-MB-175-VII	NULpRYFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\nTWM2OD1\|OT61NUBvVQ>?	NYDq[5drW0GQR1XS
MZ2-MEL	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrjTWM2OD1\|OT62OkBvVQ>?	NGjTfI9USU6JRWK=
NB5	NWC0XnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHWOZhiUUN3ME20NE43PCCwTR?=	NHOzZVNUSU6JRWK=
G-401	NYf6OWF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXe0RpR5UUN3ME20NE45OiCwTR?=	NGj1U5pUSU6JRWK=
HT	NXfzPGo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ziNmlEPTB;NEGuNFIhdk1?	NIXETGZUSU6JRWK=
8305C	M37rcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXnVFMyUUN3ME20NU45PyCwTR?=	MUXTRW5ITVJ?
BHY	NXrwWFh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHG2UFdKSzVyPUSyMlczKG6P	MYLTRW5ITVJ?
NTERA-S-cl-D1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTR\|IH7N	NVnNTYVCW0GQR1XS
T-24	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHDenlZUUN3ME20N{45OyCwTR?=	M1LQc3NCVkeHUh?=
EPLC-272H	NE\BbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL0TWM2OD12ND6zPUBvVQ>?	NYHKeFF[W0GQR1XS
PSN1	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXLTWM2OD12ND60JI5O	NELjWo9USU6JRWK=
NCI-H2452	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTHTWM2OD12ND61PEBvVQ>?	NV\jU3VXW0GQR1XS
KS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXvVVJTUUN3ME20OE43PiCwTR?=	M2PKfnNCVkeHUh?=
HD-MY-Z	NXXFTnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;tcGpDUUN3ME20OE46OiCwTR?=	MULTRW5ITVJ?
KNS-62	NGr0dVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLvTWM2OD12NT6zPEBvVQ>?	NEG3[IpUSU6JRWK=
NOMO-1	NX7qfZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq4TWM2OD12NT64O{BvVQ>?	Ml[xV2FPT0WU
SK-HEP-1	NIqwTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHZSGRmUUN3ME20Ok4xPCCwTR?=	NVjFTVY4W0GQR1XS
IGR-1	M{mxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDRU2NKSzVyPUS2MlE{KG6P	MlvvV2FPT0WU
KYSE-180	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ifVJFUUN3ME20Ok4yPyCwTR?=	MoC2V2FPT0WU
EW-22	M2i4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXyTWM2OD12Nj6yJI5O	Mkm3V2FPT0WU
NCI-H1355	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TpW2lEPTB;NE[uN\|Qhdk1?	MoPSV2FPT0WU
DOHH-2	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTR4LkO3JI5O	NV\v[JJWW0GQR1XS
A4-Fuk	M4DST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTR4LkWyJI5O	MnL6V2FPT0WU
PC-14	NXn2bm57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLi[I9KSzVyPUS2MlU4KG6P	MUnTRW5ITVJ?
TE-5	NWDEVWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfHTWM2OD12Nj64OEBvVQ>?	NFn5b3JUSU6JRWK=
LB996-RCC	NV;jU2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTR5LkG5JI5O	M{PwWXNCVkeHUh?=
NCI-H1623	NH7CZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\WTXZlUUN3ME20O{44PiCwTR?=	MULTRW5ITVJ?
NCI-H1155	M1HE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPUZYhKSzVyPUS4MlMzKG6P	MX7TRW5ITVJ?
LoVo	NFzQZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVy4Z3lkUUN3ME20PE41KG6P	M1TqTXNCVkeHUh?=
MCF7	M1zyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEG3c\|VKSzVyPUS4MlU5KG6P	NX7rfWxoW0GQR1XS
AGS	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLuTWM2OD12OD63O{BvVQ>?	MnnyV2FPT0WU
PFSK-1	M2HvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jVTWlEPTB;NEmuNFYhdk1?	M13R[XNCVkeHUh?=
22RV1	NVX3d481T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3pTWM2OD12OT6wPUBvVQ>?	M2nxTXNCVkeHUh?=
COR-L23	NFLQdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrBZY02UUN3ME20PU4yPiCwTR?=	MWHTRW5ITVJ?
D-283MED	NG\JUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP4c3E6UUN3ME20PU43OSCwTR?=	NF7kb\|JUSU6JRWK=
SW982	NE\QXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\xbmtKSzVyPUS5MlkyKG6P	NFPEPHlUSU6JRWK=
SW620	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTVyLkO2JI5O	NYHuXYo2W0GQR1XS
KYSE-140	NFTLRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nKbWlEPTB;NUCuOVUhdk1?	NV\iR4kxW0GQR1XS
GCIY	M{mwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTVyLk[3JI5O	M2D3S3NCVkeHUh?=
MHH-ESS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrKXYZjUUN3ME21NU46PSCwTR?=	NUS5S4J6W0GQR1XS
D-423MG	NGnHVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jnZWlEPTB;NUKuNFghdk1?	M3zNO3NCVkeHUh?=
SF539	NXXYWGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHWbZhKSzVyPUWyMlM2KG6P	M1XNdnNCVkeHUh?=
RPMI-2650	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjDTWM2OD13Mj62PUBvVQ>?	M{DwcHNCVkeHUh?=
GR-ST	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3KUodqUUN3ME21Nk45PyCwTR?=	NH3ae4xUSU6JRWK=
YKG-1	NGT1c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULndow{UUN3ME21N{BvVQ>?	NXvPbWhlW0GQR1XS
SK-MES-1	M12we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTV\|LkK2JI5O	MWjTRW5ITVJ?
HLE	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\VTWM2OD13Mz60O{BvVQ>?	M3K5fXNCVkeHUh?=
RVH-421	NXT3RWROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTV\|Lk[3JI5O	MnTyV2FPT0WU
C32	NEPF[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXWTWM2OD13Mz64N{BvVQ>?	M4fWVHNCVkeHUh?=
GB-1	M4jjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnCOmZKSzVyPUW0MlIhdk1?	NF;HfYxUSU6JRWK=
SNB75	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLXOmJKSzVyPUW0MlI3KG6P	MXzTRW5ITVJ?
EM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fNb2lEPTB;NUSuOEBvVQ>?	MoPDV2FPT0WU
RH-1	M2XkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTV2Lkegcm0>	MVfTRW5ITVJ?
NKM-1	NUPT[2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTV2LkixJI5O	MoPwV2FPT0WU
NCI-H2405	NYj5WG56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HPPWlEPTB;NUSuPFghdk1?	NVKwbJdIW0GQR1XS
KYSE-450	NUi2dpRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrGTWM2OD13NT6xOkBvVQ>?	MlmzV2FPT0WU
A704	M2LUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTYTWM2OD13NT61PUBvVQ>?	MWfTRW5ITVJ?
HAL-01	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTV3LkizJI5O	MWrTRW5ITVJ?
TE-11	NUO1U3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnLcHBKSzVyPUW1Mlk6KG6P	NVTGVJZjW0GQR1XS
DOK	M1[3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHBcWhKSzVyPUW2MlAzKG6P	MYLTRW5ITVJ?
KY821	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{D5UWlEPTB;NU[uNkBvVQ>?	NH;OdpFUSU6JRWK=
KGN	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELCeIFKSzVyPUW2MlMzKG6P	NWTiVGhxW0GQR1XS
MC116	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7WTWM2OD13Nz64JI5O	MXnTRW5ITVJ?
PANC-08-13	M{PiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTV6LkCxJI5O	M{KyR3NCVkeHUh?=
KE-37	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PMU2lEPTB;NUiuO\|chdk1?	MU\TRW5ITVJ?
KYSE-410	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYGwV21SUUN3ME21PU41PyCwTR?=	NYnJWYtvW0GQR1XS
RO82-W-1	M3PyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTV7Lkmgcm0>	NEnJU\|BUSU6JRWK=
M14	NVfaZoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfjSI5zUUN3ME22NE4xPCCwTR?=	NHLvZYpUSU6JRWK=
GI-1	NFfDUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvXbXZUUUN3ME22NE4{KG6P	M4HM[XNCVkeHUh?=
ML-2	NXjZ[FhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTZyLk[yJI5O	M3vEWXNCVkeHUh?=
BFTC-905	NFLYPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTZyLk[1JI5O	Mmi1V2FPT0WU
DMS-273	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3pe2JpUUN3ME22NE45PyCwTR?=	NWDiO5dHW0GQR1XS
MDA-MB-361	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH21[49KSzVyPU[xJI5O	NVe4W413W0GQR1XS
MSTO-211H	NF\tV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDjWoV3UUN3ME22N{42OSCwTR?=	NXn4NYhEW0GQR1XS
MEG-01	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfzVFdKSzVyPU[zMlUzKG6P	M1fOUXNCVkeHUh?=
M059J	NWfUdop4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTIdGRxUUN3ME22N{42QCCwTR?=	MVLTRW5ITVJ?
LN-405	M3;4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorNTWM2OD14Mz64OUBvVQ>?	NXPzNm9sW0GQR1XS
NCI-H1581	NFLKZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XKZWlEPTB;NkSuNFMhdk1?	NGH5b2pUSU6JRWK=
TCCSUP	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfuTWM2OD14ND61N{BvVQ>?	NITjdI5USU6JRWK=
SW872	NHHvNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfvTWM2OD14ND61O{BvVQ>?	MWXTRW5ITVJ?
KYSE-510	NVuwXnlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLlO\|dKSzVyPU[1Mlc2KG6P	NUXwR\|Y2W0GQR1XS
NCI-H1792	NW\DeJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnNTWM2OD14Nj6xOUBvVQ>?	M3LvenNCVkeHUh?=
SW13	NUX2T3Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV30foNLUUN3ME22Ok42KG6P	NEez[3lUSU6JRWK=
TE-8	NESzOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTZ4LkWyJI5O	M3jO[nNCVkeHUh?=
SCH	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTZ5LkGgcm0>	MkjhV2FPT0WU
NEC8	NFG5UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn34TWM2OD14Nz6yOEBvVQ>?	MVLTRW5ITVJ?
HuO-3N1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTZ5LkOxJI5O	NEPyR4dUSU6JRWK=
EFM-19	NVGySItbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDOc4NKSzVyPU[3MlUhdk1?	MWTTRW5ITVJ?
HEC-1	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTZ5LkWyJI5O	NX76N5NmW0GQR1XS
T47D	NFLCNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTZ5Lki3JI5O	MWnTRW5ITVJ?
SNU-423	M3Xh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzub\|lSUUN3ME22O{46QCCwTR?=	MXjTRW5ITVJ?
WM-115	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTZ6LkG0JI5O	NIXvT3VUSU6JRWK=
CaR-1	M1nscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmK5TWM2OD14OD6yOUBvVQ>?	NUO1Vmw6W0GQR1XS
KU812	NIXlcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTZ6Lk[5JI5O	MWHTRW5ITVJ?
AM-38	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLk[ppKSzVyPU[5MlMyKG6P	MnjXV2FPT0WU
KOSC-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXPe4FKSzVyPU[5Mlk4KG6P	MYDTRW5ITVJ?
MC-IXC	NUPWOJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7yPVJ{UUN3ME23NE4xQCCwTR?=	NGXyRYFUSU6JRWK=
SCC-4	M1PJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7ydGZKSzVyPUexMlM5KG6P	NIjR[YZUSU6JRWK=
Calu-3	NXHwWm42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGj3bmtKSzVyPUexMlk5KG6P	M2OwOnNCVkeHUh?=
RPMI-8866	NGjUcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;oOGlEPTB;N{KuPFIhdk1?	MmnNV2FPT0WU
OVCAR-4	NFzHWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrnTWM2OD15Mz6zOkBvVQ>?	MX\TRW5ITVJ?
OAW-42	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\y[5NNUUN3ME23N{4{QSCwTR?=	MVLTRW5ITVJ?
ATN-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjMTXd1UUN3ME23N{45PyCwTR?=	NXrCeYJiW0GQR1XS
CHP-212	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTd2Lkm1JI5O	MUnTRW5ITVJ?
C2BBe1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\aW3RxUUN3ME23OU4xOyCwTR?=	NV[3SpVRW0GQR1XS
A498	NXH1eHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Xve2lEPTB;N{WuNVUhdk1?	M2DhSnNCVkeHUh?=
SH-4	NFvrRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;GXGlEPTB;N{WuNlEhdk1?	NGDDZlhUSU6JRWK=
SNU-449	NXjVfY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTd3Lke5JI5O	MX3TRW5ITVJ?
RD	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;FfoVKSzVyPUe1Mlg3KG6P	NEm3VJRUSU6JRWK=
PANC-03-27	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T3TGlEPTB;N{[uNlUhdk1?	M2ThV3NCVkeHUh?=
S-117	NI\wPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTd4LkK3JI5O	M4XVbHNCVkeHUh?=
SK-MEL-2	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3tXHRVUUN3ME23Ok44PSCwTR?=	Mlf6V2FPT0WU
LK-2	NWK0WYI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTd5LkC1JI5O	MonnV2FPT0WU
CP50-MEL-B	M3rneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDnRnVSUUN3ME23O{41KG6P	NEfPSotUSU6JRWK=
647-V	NUOxTVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHPTWM2OD15OD6wO{BvVQ>?	NXy1cXJZW0GQR1XS
LU-134-A	NF;SdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X5c2lEPTB;N{muNFMhdk1?	M2nGU3NCVkeHUh?=
5637	M37Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:0N2lEPTB;N{muNlMhdk1?	M1LSVnNCVkeHUh?=
NCI-H1437	M4fU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r5SWlEPTB;OECuOUBvVQ>?	M{DI[XNCVkeHUh?=
NCI-H460	M{D3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PyeGlEPTB;OEGuNlMhdk1?	NGnUd5dUSU6JRWK=
BxPC-3	M13xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13wemlEPTB;OEGuOFYhdk1?	NXjGbYY6W0GQR1XS
CAN	NFWwTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\VfWlEPTB;OEGuPFQhdk1?	M2mydXNCVkeHUh?=
KINGS-1	NE\LXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHaTWM2OD16Mj6zNkBvVQ>?	NVjTb5pPW0GQR1XS
OCUB-M	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf1dJFKSzVyPUiyMlQyKG6P	NVnvW2N6W0GQR1XS
KALS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\0e41TUUN3ME24Nk42PCCwTR?=	M2[yOXNCVkeHUh?=
OCI-AML2	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzMTWM2OD16Mj62NUBvVQ>?	M2jnfXNCVkeHUh?=
A253	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorHTWM2OD16Mj62OUBvVQ>?	NF\yenVUSU6JRWK=
LCLC-97TM1	NEnwfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzrVllKSzVyPUiyMlg3KG6P	M2nXfnNCVkeHUh?=
NCI-H520	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;vTWM2OD16Mz6wOkBvVQ>?	MmHRV2FPT0WU
P30-OHK	NXTOc4I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7ke4JKSzVyPUizMlUhdk1?	NFyyU\|NUSU6JRWK=
SBC-5	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXVU486UUN3ME24N{42OiCwTR?=	MYLTRW5ITVJ?
HCE-T	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojXTWM2OD16Mz63OEBvVQ>?	M1fWeHNCVkeHUh?=
JEG-3	M2fXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\KTWM2OD16ND6xJI5O	NIHWSIpUSU6JRWK=
KG-1	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnmxTWM2OD16ND6yOEBvVQ>?	MVHTRW5ITVJ?
MIA-PaCa-2	NWrlb2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYS2dFZYUUN3ME24OE42PCCwTR?=	NEm0T2xUSU6JRWK=
CAL-33	NXPXT5liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLrbYpKSzVyPUi1MlA5KG6P	NWPlW5RNW0GQR1XS
639-V	M3nTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknVTWM2OD16NT60NkBvVQ>?	M1LO[XNCVkeHUh?=
NCI-H1048	NIDmU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYq1PHdEUUN3ME24Ok4{OSCwTR?=	MYPTRW5ITVJ?
NCI-H1573	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvkTWM2OD16Nz60PEBvVQ>?	NYn5bpU6W0GQR1XS
NCI-H2228	NUTzNXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfBbXdKSzVyPUi4MlI3KG6P	M1vw[XNCVkeHUh?=
NB14	M3r2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fl[2lEPTB;OEiuN{BvVQ>?	MYjTRW5ITVJ?
SCC-25	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPseXBKSzVyPUi5MlgzKG6P	MkWyV2FPT0WU
A431	NH70WJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHLNlRoUUN3ME24PU46PyCwTR?=	M3i5cXNCVkeHUh?=
SN12C	NHy0e2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTlyLk[yJI5O	NYTadGxsW0GQR1XS
HuCCT1	NWfuN3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnqd45bUUN3ME25NE44PiCwTR?=	NH\DTHNUSU6JRWK=
LS-123	NW\1dnNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[0bWlEPTB;OUKuNVghdk1?	MoTvV2FPT0WU
CAL-85-1	NIHu[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[yZYJKSzVyPUmyMlQ5KG6P	M1LDWHNCVkeHUh?=
ES6	NUjLSZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDPSYl5UUN3ME25Nk45OyCwTR?=	NGXDTHBUSU6JRWK=
NCI-H650	NEm4WXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTl2LkC5JI5O	MY\TRW5ITVJ?
NCI-H446	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPi[JZKSzVyPUm1MlEzKG6P	NXjQNXV2W0GQR1XS
EW-13	NGSwc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEK0WHRKSzVyPUm1Mlc2KG6P	M3X1OHNCVkeHUh?=
HSC-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6xVo5KSzVyPUm1Mlg6KG6P	MUPTRW5ITVJ?
U031	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjaepJKSzVyPUm2Mlc{KG6P	NX24OmlCW0GQR1XS
EW-11	M4fYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfhWXNKSzVyPUm2Mlg5KG6P	M1XFbHNCVkeHUh?=
GAK	NEjzNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Pt[mlEPTB;OUiuPVMhdk1?	NEjmNZZUSU6JRWK=
SK-OV-3	NHXEc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HBV2lEPTB;MUCwMlA4KG6P	NVHKSW5UW0GQR1XS
OMC-1	NX62SZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXEcpZKSzVyPUGwNE4yQCCwTR?=	MlT6V2FPT0WU
TK10	M2Hh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFyMD6yNUBvVQ>?	NGn0Z4xUSU6JRWK=
EKVX	NYn5eodYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7GdGFKSzVyPUGwNE43KG6P	NFvPc2tUSU6JRWK=
Detroit562	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXpcmZ1UUN3ME2xNFIvOTdibl2=	NGq0WIVUSU6JRWK=
SF268	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7Rdo1LUUN3ME2xNFIvOzRibl2=	MmntV2FPT0WU
SNU-387	NWXoeVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTpO4tKSzVyPUGwOE4yPyCwTR?=	M2rLTnNCVkeHUh?=
MDA-MB-231	NW\lXIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j1RmlEPTB;MUC1MlA3KG6P	MYTTRW5ITVJ?
NCI-H1563	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFyNT6xPEBvVQ>?	M4rafXNCVkeHUh?=
D-502MG	NGLGToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;kdWlEPTB;MUC1Mlchdk1?	NF\MXJFUSU6JRWK=
A2780	NVvicVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTFyNj60O{BvVQ>?	MYrTRW5ITVJ?
IA-LM	NFnMTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PncGlEPTB;MUC3MlUyKG6P	MV;TRW5ITVJ?
D-392MG	NF3nTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXqzT\|duUUN3ME2xNFcvPTRibl2=	NIe3Z3JUSU6JRWK=
MS-1	NH21eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHVXXRKSzVyPUGwO{44OSCwTR?=	M37UVnNCVkeHUh?=
SW1990	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFyOD61OEBvVQ>?	NHzNR3dUSU6JRWK=
HEL	NHXPWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jTUWlEPTB;MUC5MlI6KG6P	NYXESm9mW0GQR1XS
SW1573	NEi5[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorCTWM2OD1zMEmuN\|Ehdk1?	M3\KUXNCVkeHUh?=
SW1783	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTWTWM2OD1zMUCuNlIhdk1?	M{XjUHNCVkeHUh?=
COLO-680N	M4\aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPyemZKSzVyPUGxNE44PiCwTR?=	M1vCN3NCVkeHUh?=
NCI-N87	M2LvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPjOW9oUUN3ME2xNVEvODRibl2=	MX;TRW5ITVJ?
SK-MEL-28	M3nIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID5W29KSzVyPUGxNU42PSCwTR?=	NYLUTI1oW0GQR1XS
BT-20	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFzMj6wNUBvVQ>?	MW\TRW5ITVJ?
NCI-H1648	NInmcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\5OWlEPTB;MUGzJI5O	MWDTRW5ITVJ?
no-11	NXrGR4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTSb2pFUUN3ME2xNVMvOjhibl2=	MX7TRW5ITVJ?
MOLT-13	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjLXYxKSzVyPUGxN{41PCCwTR?=	M{nqfHNCVkeHUh?=
NCI-H2170	M{LRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17LXWlEPTB;MUG0MlUyKG6P	M1S4WXNCVkeHUh?=
HTC-C3	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnmO5lXUUN3ME2xNVYvQDVibl2=	M4XEcnNCVkeHUh?=
LU-99A	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnoNHlnUUN3ME2xNVcvOjFibl2=	MULTRW5ITVJ?
HCC2998	NELiPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDYbJlKSzVyPUGxO{46OiCwTR?=	MkjXV2FPT0WU
NB13	NIT6[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{OzSmlEPTB;MUG3Mlk6KG6P	NV;4PVZEW0GQR1XS
GT3TKB	M3THNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPYfYpQUUN3ME2xNVgvODhibl2=	NXW0O\|VxW0GQR1XS
BT-549	NEnqZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPtPFJJUUN3ME2xNVgvQTVibl2=	MoHFV2FPT0WU
NCI-H747	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHVN5VzUUN3ME2xNVkvOzRibl2=	NED6dXBUSU6JRWK=
EW-1	NGn6TpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTVUlBKSzVyPUGyNE4zKG6P	M{nO[HNCVkeHUh?=
LB831-BLC	NWLlOnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF{MD62N{BvVQ>?	M4\6XnNCVkeHUh?=
NMC-G1	M3jwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2iyd2lEPTB;MUKxMlEyKG6P	M3HWV3NCVkeHUh?=
COLO-679	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETtdnVKSzVyPUGyNk4yPSCwTR?=	NYfvT29PW0GQR1XS
HL-60	NXfHW5ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfRSnl7UUN3ME2xNlMvOSCwTR?=	NEO2TYtUSU6JRWK=
MKN7	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2CzTWlEPTB;MUKzMlg{KG6P	MUPTRW5ITVJ?
RERF-LC-MS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTF{ND6zNUBvVQ>?	M4XjeHNCVkeHUh?=
DMS-114	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjBXW9KSzVyPUGyOU4xQSCwTR?=	NXHSdms1W0GQR1XS
HuP-T4	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS4TWM2OD1zMk[uPVchdk1?	MXzTRW5ITVJ?
HCC2157	NXX4WXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljLTWM2OD1zMkeuOUBvVQ>?	Ml3KV2FPT0WU
SKG-IIIa	NXLyVno4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF{OD64JI5O	MnnsV2FPT0WU
HCT-116	NH;DNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH62SVRKSzVyPUGzNE43PCCwTR?=	MWXTRW5ITVJ?
BB30-HNC	NUTtcZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu3WpRDUUN3ME2xN\|AvPzhibl2=	M4HpT3NCVkeHUh?=
KYSE-270	M1TCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrkTWM2OD1zM{CuPFghdk1?	M1X5fnNCVkeHUh?=
MFM-223	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTYN3pKSzVyPUGzNU42OSCwTR?=	NHnsOWxUSU6JRWK=
NH-12	NILWT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfETWM2OD1zM{KuPVkhdk1?	Ml;RV2FPT0WU
U-118-MG	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3NSHI6UUN3ME2xN\|MvPjJibl2=	Mme5V2FPT0WU
ESS-1	NF;BV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDBc\|JKSzVyPUGzOU4yQCCwTR?=	NVjy[IJjW0GQR1XS
D-247MG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17pfWlEPTB;MUO1MlIyKG6P	MkLtV2FPT0WU
IGROV-1	NFjrZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXf2XJA2UUN3ME2xN\|UvPzZibl2=	NH3ub5BUSU6JRWK=
C-33-A	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO4XJNKSzVyPUGzOU46PyCwTR?=	NIXtVIRUSU6JRWK=
NCI-H1693	M1S1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nNRmlEPTB;MUO2MlEzKG6P	MVrTRW5ITVJ?
MLMA	M{nISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\OWmZKSzVyPUGzOk42QCCwTR?=	MXvTRW5ITVJ?
SK-N-AS	NHLENWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF\|Nz6xO{BvVQ>?	MmCyV2FPT0WU
NCI-H1755	M1\WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF\|OD64OUBvVQ>?	MmfuV2FPT0WU
CHP-134	M4jqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF\|OT61OUBvVQ>?	NVuwNoNEW0GQR1XS
LS-513	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTF2MD65NUBxVQ>?	NUPOcmxSW0GQR1XS
TE-12	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4L2SmlEPTB;MUSwMlk{KG6P	M3rJPXNCVkeHUh?=
KNS-42	NXnoNJczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF2ND6zJI5O	M1z1TnNCVkeHUh?=
SJRH30	NGL3WHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF2ND60OEBvVQ>?	NEPONlNUSU6JRWK=
NCI-H1092	NXPZfm9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfRT2h5UUN3ME2xOFQvPTJibl2=	NH\5Z\|BUSU6JRWK=
H-EMC-SS	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXMTWM2OD1zNE[uPFEhdk1?	Ml7qV2FPT0WU
SK-MEL-3	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF2Nz61OUBvVQ>?	NInMNJZUSU6JRWK=
SK-N-FI	NYS4SJhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrIUm1KSzVyPUG0O{42QSCwTR?=	M2m0UXNCVkeHUh?=
NCI-H2126	M2rwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoL3TWM2OD1zNEiuNVUhdk1?	Mo[yV2FPT0WU
NCI-H1299	NWjvVXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXBSo5kUUN3ME2xOVAvOjJibl2=	NYHtbIFxW0GQR1XS
CFPAC-1	NXO5Z25ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzvTWM2OD1zNUCuOlYhdk1?	M4PNd3NCVkeHUh?=
NCI-H661	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\3c2lEPTB;MUWxMlI3KG6P	NFHlUZlUSU6JRWK=
KYSE-70	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[zN3JYUUN3ME2xOVEvPzlibl2=	MlT6V2FPT0WU
SW900	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LPbGlEPTB;MUW0MlY2KG6P	MmnsV2FPT0WU
Ca-Ski	NH\sUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXKTWM2OD1zNU[uN\|khdk1?	MoLQV2FPT0WU
HPAF-II	M33je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlznTWM2OD1zNU[uOFchdk1?	NUflO4FsW0GQR1XS
LB2518-MEL	NYn4c2htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\JN\|QxUUN3ME2xOVcvOSCwTR?=	MXLTRW5ITVJ?
LC-2-ad	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmq0TWM2OD1zNUiuOlIhdk1?	M1f1NnNCVkeHUh?=
HCC1806	NVm0em57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTF4Nz64PEBvVQ>?	M{LCRXNCVkeHUh?=
UACC-62	M3;zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYGxU4lbUUN3ME2xOlgvODlibl2=	MWjTRW5ITVJ?
KM-H2	M1PXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjCV5ZKSzVyPUG3NE42QCCwTR?=	NGfzPZVUSU6JRWK=
NCI-H2347	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTF5Mj63NkBvVQ>?	MV\TRW5ITVJ?
SCC-15	NUHF[2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFK3bI9KSzVyPUG3N{43PiCwTR?=	NUfCUFFTW0GQR1XS
BB49-HNC	NV;sPIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHHW5g1UUN3ME2xO\|MvQDFibl2=	M3yzV3NCVkeHUh?=
GMS-10	NUPNb\|F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH25NWVKSzVyPUG3N{46PCCwTR?=	NU\BRnNlW0GQR1XS
NCI-H2052	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjqTWM2OD1zN{SuPUBvVQ>?	MkL5V2FPT0WU
SW626	M4HNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfTfZBKSzVyPUG3Ok4xPiCwTR?=	M1LpTHNCVkeHUh?=
MDA-MB-415	NHTSeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\4[mlEPTB;MUe2MlYyKG6P	MULTRW5ITVJ?
Saos-2	NIfkfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoflTWM2OD1zN{muN\|Uhdk1?	MVHTRW5ITVJ?
DK-MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\vTWM2OD1zOECuN{BvVQ>?	Ml7DV2FPT0WU
SNU-C2B	M2nsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LLNWlEPTB;MUiwMlc{KG6P	NV3NRmcxW0GQR1XS
A427	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjFW\|RKSzVyPUG4Nk42PyCwTR?=	Ml7tV2FPT0WU
KP-N-YS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXWzSHJvUUN3ME2xPFUhdk1?	Mlv5V2FPT0WU
J82	M4DDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPlTZU1UUN3ME2xPFUvOThibl2=	MUjTRW5ITVJ?
LS-411N	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L2OmlEPTB;MUi3MlI5KG6P	NIDtTXRUSU6JRWK=
HCC1937	NXHud5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfJSY1KSzVyPUG4O{41QSCwTR?=	MYLTRW5ITVJ?
OE33	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonZTWM2OD1zOEiuPVchdk1?	Mn;5V2FPT0WU
NB7	NFXsW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3l[YlKSzVyPUG4PU45QSCwTR?=	M1;6UnNCVkeHUh?=
SW684	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPQN3FKSzVyPUG5Ok4yOyCwTR?=	M4nNR3NCVkeHUh?=
HT-144	NYP6Z2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3GcWdKSzVyPUG5Ok4yPSCwTR?=	NV;Pc3F{W0GQR1XS
SK-MEL-30	M3jFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF7Nj6yJI5O	M3j3dHNCVkeHUh?=
DBTRG-05MG	NXjSWIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf0TWM2OD1zOUiuOFchdk1?	NFOwZnJUSU6JRWK=
NCI-H1395	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmi0TWM2OD1zOUiuPFUhdk1?	M370bHNCVkeHUh?=
NCI-H2122	M3nTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV65XWhDUUN3ME2yNFAvPTlibl2=	MXXTRW5ITVJ?
no-10	M2W0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2joRWlEPTB;MkCxMlA1KG6P	MVLTRW5ITVJ?
SW48	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\a[GlEPTB;MkCxMlMyKG6P	MlTNV2FPT0WU
NCI-H1650	M3;kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHYTWM2OD1{MESuNFEhdk1?	MUfTRW5ITVJ?
MZ1-PC	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLRTWM2OD1{MEWuOVghdk1?	NWrLW21RW0GQR1XS
U-266	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXSU4RKSzVyPUKwOU44QSCwTR?=	MVTTRW5ITVJ?
CAS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLHeppWUUN3ME2yNFcvPDRibl2=	MVjTRW5ITVJ?
AU565	M3e3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHvdHZKSzVyPUKxNk45OiCwTR?=	MV3TRW5ITVJ?
UACC-257	M1m5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\FbmlEPTB;MkGzMlk6KG6P	NEK1TZlUSU6JRWK=
CAL-27	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vjd2lEPTB;MkG3MlA2KG6P	MYTTRW5ITVJ?
NCI-H23	NHTIeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPjTWM2OD1{MUmuN\|Mhdk1?	NFXC[41USU6JRWK=
TE-6	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTJzOT62PEBvVQ>?	NFvROodUSU6JRWK=
TGBC24TKB	NET3S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS1TWM2OD1{MkKuNVchdk1?	M4LDZ3NCVkeHUh?=
TE-1	NX[4eJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDjTWM2OD1{MkKuPFghdk1?	MVnTRW5ITVJ?
RCC10RGB	NH31coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJ{ND6xPUBvVQ>?	MnHFV2FPT0WU
NCI-H596	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3XTWM2OD1{MkiuNlIhdk1?	MnT4V2FPT0WU
SW954	NVn5T3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\KemlEPTB;MkOzMlg{KG6P	MlXEV2FPT0WU
NCI-H2087	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fnTmlEPTB;MkO0MlUyKG6P	MWDTRW5ITVJ?
SK-PN-DW	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLpTWM2OD1{M{WuNVkhdk1?	NV7YVWZHW0GQR1XS
KM12	NIPPW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr2OndKSzVyPUKzOU44KG6P	MX3TRW5ITVJ?
BT-474	M33Td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPVS4hKSzVyPUKzOU44OyCwTR?=	MVLTRW5ITVJ?
IST-MES1	NHvBVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJ\|Nj61O{BvVQ>?	NIrCW5FUSU6JRWK=
HT-1197	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJ\|OD6wPUBvVQ>?	NELGOI1USU6JRWK=
CAL-54	NEXOXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjZU\|ZKSzVyPUKzPE41QSCwTR?=	NXS5UYZRW0GQR1XS
NB10	NXPpZZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;0R2lEPTB;MkSwMlA3KG6P	M1noSnNCVkeHUh?=
PANC-10-05	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJ2NT61OkBvVQ>?	MXTTRW5ITVJ?
NCI-H522	NVTVN21zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1OyO2lEPTB;MkS4MlMyKG6P	MYfTRW5ITVJ?
A388	NWrTSJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzQWVVKSzVyPUK0PU45OiCwTR?=	Mlj4V2FPT0WU
GOTO	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ3MD6yPUBvVQ>?	M{PpS3NCVkeHUh?=
KLE	NXrNSZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HsOGlEPTB;MkWxMlg4KG6P	MnOxV2FPT0WU
KYSE-520	M3;Ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3GwUGlEPTB;MkWyMlg3KG6P	NV7QXohDW0GQR1XS
HCE-4	NED5eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DQbWlEPTB;Mk[yMlUhdk1?	MXzTRW5ITVJ?
KURAMOCHI	M2jsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ4NT65JI5O	NIH1UJpUSU6JRWK=
HCC38	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvIUHFHUUN3ME2yOlYvPDhibl2=	M2P6d3NCVkeHUh?=
FADU	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\hS2lEPTB;Mk[2MlY{KG6P	Mke1V2FPT0WU
CW-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3HNpFQUUN3ME2yOlkvQTZibl2=	NV\NXoxtW0GQR1XS
L-428	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJ5NT6xOUBvVQ>?	NUDUTmNlW0GQR1XS
HCC1569	NYWyXZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\Ubnh7UUN3ME2yO\|UvQDRibl2=	Mn3oV2FPT0WU
NCI-H810	M4jRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnwfGRKSzVyPUK3PE4{OSCwTR?=	NUXRe3ljW0GQR1XS
LB771-HNC	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfaPYZrUUN3ME2yPFUvQDRibl2=	MWHTRW5ITVJ?
LCLC-103H	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe1TWM2OD1{OEWuPVkhdk1?	M2iyb3NCVkeHUh?=
EFO-21	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\1Tm85UUN3ME2yPFcvPjhibl2=	NFGxbIlUSU6JRWK=
CAL-72	NV7PWmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\Pd2VKSzVyPUK5N{4yQSCwTR?=	NWTyVnBRW0GQR1XS
SCC-9	M{LkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XRe2lEPTB;MkmzMlIzKG6P	M3;wS3NCVkeHUh?=
COLO-829	NFjZbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJ7Nj61JI5O	NXzncYRSW0GQR1XS
U-87-MG	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3yTWM2OD1\|MECuO\|Mhdk1?	M{TvSXNCVkeHUh?=
MZ7-mel	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K2dmlEPTB;M{KzMlc3KG6P	MVvTRW5ITVJ?
NCI-H1770	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zXU2lEPTB;M{K2Mlc1KG6P	M4\nb3NCVkeHUh?=
ChaGo-K-1	NEnj[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTN{OD6xJI5O	MnnTV2FPT0WU
SiHa	NEDaeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXP0bYV5UUN3ME2zNlkvOjRibl2=	NHGwNFJUSU6JRWK=
NCI-SNU-5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUD6WmRvUUN3ME2zN\|YvPzdibl2=	M2GzWXNCVkeHUh?=
DJM-1	NVPBeG1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTN2MD6zN{BvVQ>?	MVrTRW5ITVJ?
OE19	NXrNcG5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33CS2lEPTB;M{SwMlU{KG6P	M12yXXNCVkeHUh?=
NCI-H1651	NV7KVo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPCNY9KSzVyPUO0OE4yQCCwTR?=	M2X3UHNCVkeHUh?=
COLO-792	M3jNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PlbGlEPTB;M{W0MlQzKG6P	NEHTS3FUSU6JRWK=
ACHN	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPZTWM2OD1\|NU[uO\|Ehdk1?	M3mxdnNCVkeHUh?=
TH-3	M37RXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILjfldKSzVyPUO3PU46PSCwTR?=	M3zLeXNCVkeHUh?=
HT-1376	NY[3VpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTN6ND64PEBvVQ>?	NYno[FU3W0GQR1XS
RH-18	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrNRZZKSzVyPUO5OE44PCCwTR?=	NFTrPJNUSU6JRWK=
NB6	NIfHWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDOVWlKSzVyPUO5Ok43PiCwTR?=	NVWwR\|V6W0GQR1XS
COLO-320-HSR	NXjWTJdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzm[Y1DUUN3ME20NFMvOzdibl2=	NIq1dpJUSU6JRWK=
UACC-893	Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXe2fIo3UUN3ME20NFYvPDdibl2=	NGLxO2NUSU6JRWK=
DSH1	NYq5WHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP5SFRKSzVyPUSwOk46OSCwTR?=	MYTTRW5ITVJ?
TE-10	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTRyNz6wNUBvVQ>?	MWHTRW5ITVJ?
HCC70	NY\DWnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXwdnNYUUN3ME20NFkvOjFibl2=	MUXTRW5ITVJ?
TGBC11TKB	NV32Z2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3GwVWlEPTB;NEGwMlM{KG6P	NX3LSVZLW0GQR1XS
NCI-H727	NF;HW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTRzMj6xNUBvVQ>?	M{DsOXNCVkeHUh?=
ALL-PO	NIK3W\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTRzNT62PUBvVQ>?	MUHTRW5ITVJ?
ABC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmraTWM2OD12MkCuOFUhdk1?	MWrTRW5ITVJ?
NCI-H69	M{WySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTR{Nj63OkBvVQ>?	M{nnRXNCVkeHUh?=
GP5d	NEDwdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[2WIc3UUN3ME20N\|QvPDFibl2=	MoDrV2FPT0WU
UMC-11	NH31[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTR3OD6zOkBvVQ>?	Ml7hV2FPT0WU
RMG-I	M1nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTR4Nz61OkBvVQ>?	M2ToTXNCVkeHUh?=
YAPC	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;LW2lEPTB;NEmwMlYhdk1?	Mo\IV2FPT0WU
LS-1034	M17Wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LwUGlEPTB;NEmxMlA3KG6P	NVrN[oV3W0GQR1XS
RCM-1	NFPod25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTR7Nj62PEBvVQ>?	NEf5fXRUSU6JRWK=
HCC1954	NYL1PZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjMc4VKSzVyPUWxNk42KG6P	MYXTRW5ITVJ?
SK-MEL-24	NVvGSW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTVzNj61NUBvVQ>?	M3LjTHNCVkeHUh?=
NB12	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTV{OD60NkBvVQ>?	M3rFfnNCVkeHUh?=
SW756	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjSfWNKSzVyPUW1OE46PiCwTR?=	NVjO[2RJW0GQR1XS
HCC1187	NUjpNJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X1TWlEPTB;NUe1Mlg{KG6P	NHviZ2FUSU6JRWK=
NCI-H2342	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnniTWM2OD13OUCuN\|khdk1?	MkTxV2FPT0WU
NCI-H2291	NXrYRodYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fNW2lEPTB;NUm4MlMyKG6P	MWrTRW5ITVJ?
OVCAR-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHThXI5KSzVyPUW5PE46PiCwTR?=	NVzrTFRvW0GQR1XS
MHH-NB-11	NUHOV4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTZ{OT6wNUBvVQ>?	NVzkXJVSW0GQR1XS
SAS	M2nVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vVd2lEPTB;NkWyMlY4KG6P	NY\qUI95W0GQR1XS
COLO-824	NFfUcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPTe5NKSzVyPU[4PU4{PyCwTR?=	NHiwPJhUSU6JRWK=
HCC1395	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTrTWM2OD14OUiuOUBvVQ>?	MljDV2FPT0WU
COLO-668	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTdyNj6xJI5O	M2\sfnNCVkeHUh?=
NCI-H226	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PTbWlEPTB;N{C3Mlghdk1?	NHr6T2dUSU6JRWK=
NB17	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XBfWlEPTB;N{KxMlc2KG6P	MV;TRW5ITVJ?
SW1463	NYHkTnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTd\|OT6xPUBvVQ>?	MoXFV2FPT0WU
TGW	NHXBfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHiTWM2OD15NkCuNVUhdk1?	MkTQV2FPT0WU
NCI-H526	NYfwdoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPzfYNLUUN3ME24NlMvPTNibl2=	NGK4NYFUSU6JRWK=
COR-L88	NV\VTm5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTh2OD6xNkBvVQ>?	M3LUdXNCVkeHUh?=
NCI-H441	M330bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;vTWM2OD16OUWuNlIhdk1?	NFn0NlRUSU6JRWK=
NCI-H630	M3;hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTlzMj65OkBvVQ>?	NWjOOXpXW0GQR1XS
Mo-T	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELre\|ZKSzVyPUm0O{45QCCwTR?=	NHrOUYJUSU6JRWK=
JAR	NU\jSWJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTl3Nj6yOEBvVQ>?	MX3TRW5ITVJ?
NCI-H1838	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfZOZZmUUN3ME2xMlAzOzh6IN88US=>	NXvYbHNbW0GQR1XS
DoTc2-4510	NVnte5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXwUZhKSzVyPUGuNFc{PzZizszN	M4TZfXNCVkeHUh?=
MKN28	M2\rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknjTWM2OD1zLkC5NFI1KM7:TR?=	MnLrV2FPT0WU
HuP-T3	M2XvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPkVIw3UUN3ME2xMlEyQTB3IN88US=>	MYfTRW5ITVJ?
TE-9	NHnMd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXpeIZxUUN3ME2xMlEzQTd\|IN88US=>	NHS1OlFUSU6JRWK=
NY	MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\2b21EUUN3ME2xMlE3Pzl{IN88US=>	NFX1Z\|RUSU6JRWK=
HT55	NFTWfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TpW2lEPTB;MT6zNVM1PCEQvF2=	MnXtV2FPT0WU
SW837	M3LJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13ye2lEPTB;MT6zNlk4QCEQvF2=	MWjTRW5ITVJ?
NCI-H2029	M33sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHNUZlKSzVyPUGuOFE4QTFizszN	MnvQV2FPT0WU
IST-SL1	NHj2SItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DCPWlEPTB;MT60OFI1KM7:TR?=	NV;0TW1JW0GQR1XS
COLO-741	NFHuXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwNEm3O\|Eh\|ryP	MUDTRW5ITVJ?
LU-65	NHS5VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTFwNkKyOFkh\|ryP	NYHKNZlpW0GQR1XS
NCI-H1304	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j6NWlEPTB;MT62OVQ6QCEQvF2=	NY\5SFhMW0GQR1XS
KARPAS-299	M4TuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrrTWM2OD1zLke5OFc6KM7:TR?=	M3nQXnNCVkeHUh?=
NCI-H358	MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfWUGtKSzVyPUGuPVU2ODNizszN	MXnTRW5ITVJ?
OAW-28	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;6TWM2OD1{LkC2PVE6KM7:TR?=	MnXCV2FPT0WU
C8166	NGHFN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnm0TWM2OD1{Lk[zN\|kzKM7:TR?=	M3v4SnNCVkeHUh?=
COLO-678	NHO3bGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFi2[5JKSzVyPUKuPFM4PjhizszN	M3HiWnNCVkeHUh?=
SK-N-DZ	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDsTWM2OD1{Lki2N\|gyKM7:TR?=	NUfnZm9zW0GQR1XS
NCI-H82	NELkWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVy5UGpYUUN3ME2yMlkxOzZ7IN88US=>	NHOzUY9USU6JRWK=
JVM-2	NFXwW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfHN\|BKSzVyPUOuNFMyQDhizszN	M2OyenNCVkeHUh?=
SW1116	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjxUIozUUN3ME2zMlA2PDFzIN88US=>	Mli2V2FPT0WU
MDA-MB-453	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTNwMUC0N\|kh\|ryP	NFm0blNUSU6JRWK=
Calu-6	NETDXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnR[IRKSzVyPUOuNVk6PyEQvF2=	MnfKV2FPT0WU
SHP-77	NH3UXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNwNUK4JO69VQ>?	MWXTRW5ITVJ?
Capan-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7oTWM2OD12LkOyOVgyKM7:TR?=	MmrxV2FPT0WU
SW948	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nEZWlEPTB;ND63OFc4QSEQvF2=	MnLDV2FPT0WU
HDLM-2	M{PETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD0WJlKSzVyPUWuNFc4OjVizszN	NGDCWVlUSU6JRWK=
LAN-6	M{DLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLkcZJWUUN3ME22MlIyPDl3IN88US=>	NHfSZoxUSU6JRWK=
LU-135	NFnaeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO3bnBKSzVyPU[uOFMxPzdizszN	NVPV[YQ3W0GQR1XS
T84	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW2ZY91UUN3ME22Mlk5PjRizszN	MonIV2FPT0WU
CAPAN-1	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF24WZdKSzVyPUeuOlIzOzNizszN	NH6w[WxUSU6JRWK=
SW1417	NGK5c5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\je2lIUUN3ME23MlkyPzNzIN88US=>	M3LkWXNCVkeHUh?=
BALL-1	M17Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknOTWM2OD16LkWwOFA6KM7:TR?=	NF2yU2ZUSU6JRWK=
HT-29	NWe4enc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIO1XZRKSzVyPUmuNFc2QTlizszN	NWPUU3FNW0GQR1XS
C3A	NIrMOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrWXW5yUUN3ME25Mlg5Ozl2IN88US=>	MYfTRW5ITVJ?
NCI-H1993	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXX[XVKSzVyPUGwMlUxQDFizszN	MnHFV2FPT0WU
SK-MEL-1	NHTNfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPlfWF{UUN3ME2xNU43Ojh7IN88US=>	MoHoV2FPT0WU
DU-145	NXrhbpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF2LkWwOVIh\|ryP	MUfTRW5ITVJ?
KP-N-YN	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnQe2ZRUUN3ME2xOE42OTB\|IN88US=>	MUfTRW5ITVJ?
CCRF-CEM	M2D0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTv[os2UUN3ME2xOE44QDB7IN88US=>	MoHzV2FPT0WU
ZR-75-30	M2HGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTF4LkOzNFMh\|ryP	NFHzcmJUSU6JRWK=
A673	NHHjcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTJyLkW1NFch\|ryP	M4Kxe3NCVkeHUh?=
K-562	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS3TWM2OD1{OD60NVg{KM7:TR?=	M2LJZnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	+ Expand Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+polyethylene glycol 300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT00620594	Completed	Breast Cancer\|Advanced Solid Tumors\|Cowden Syndrome	Novartis Pharmaceuticals\|Novartis	December 21 2006	Phase 1
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01658436	Completed	Pancreatic Neuroendocrine Tumors (pNET)	Novartis Pharmaceuticals\|Novartis	November 2012	Phase 2
NCT01628913	Terminated	Pancreatic Neuroendocrine Tumors (pNET)	Novartis Pharmaceuticals\|Novartis	October 2012	Phase 2
NCT01690871	Withdrawn	Malignant PEComa (Perivascular Epithelioid Cell Tumors)	Novartis Pharmaceuticals\|Novartis	September 2012	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 84 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 84 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)